Evotec stock at EUR 2.82 ahead of the Xetra open: biotech group rises 0.71 percent
Published on 10/27/2026 at 07:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and reporting date
- Evotec develops medicines with partners through data-driven research and drug-development services.
- Full results for the third quarter and first nine months are scheduled for November 5, 2026.
- Evotec stock trades pre-market at EUR 2.82 at 7:54 a.m. CET at Lang & Schwarz on October 27, 2026, 0.71 percent above the Xetra close of October 26, 2026.
Evotec develops and researches medicines with partners by combining scientific expertise, data-driven research and technology platforms, with revenue linked to services, milestones, licenses and commercial partnerships, according to the company’s Investor Relations materials. Evotec stock trades pre-market at EUR 2.82 at 7:54 a.m. CET at Lang & Schwarz on October 27, 2026, 0.71 percent above the Xetra close of October 26, 2026 (EUR 2.80).
Pre-market indication
The indication is EUR 0.02 above the Xetra close. The bid is EUR 2.80 and the ask EUR 2.83, a spread of 1.06 percent that indicates thin pre-market trading. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Evotec stock.
Business model and reporting date
Evotec works with pharmaceutical and biotechnology partners on drug discovery and development, while its activities also include technology platforms, biologics manufacturing and partner-related milestone and licensing income, as described by the company’s Investor Relations materials. The company’s full third-quarter and nine-month results are listed for November 5, 2026, in the company coverage. Market context: Market report DAX.
